Control Network Neuromodulation to Enhance Cognitive Training in Complex Traumatic Brain Injury
Key facts
- Who runs it
- University of New Mexico
- Where
- Albuquerque and Minneapolis, United StatesSee the 5 sites
- Trial code
- Status
- Recruiting
- People taking part
- 108 people, planned
- Started
- 21 Jan 2022
- Expected to end
- 1 Nov 2027
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- rTMS
- HD-tDCS
- Attention Process Training
- Record updated
- 14 October 2026
Who can take part
- Age
- 18 years to 59 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- There will be no gender restrictions with regard to sample inclusion. Veterans and Warfighters will be enrolled in this study if they 1) are aged 18-59; 2) have suffered a mild TBI with documented evidence of alteration in neurological functioning or loss of consciousness (LOC) which was less than 30 minutes; 3) were injured between 3 months and 5 years ago; 4) experienced less than 24 hours of post-traumatic amnesia (PTA); 5) have subjective post-TBI cognitive deficits as assessed by the NSI, with at least 1 of 4 cognitive symptoms at a score of 3 or higher (severe disturbance) or at least 2 of 4 cognitive symptoms at a score of 2 or higher (moderate disturbance). This is the target population as identified by the grant mechanism, with chronic cognitive impairments from mild traumatic brain injury. The age range of 18-59 years was selected because the investigators did not want to include developmental processes in analyses and by 18 years old, many major neurodevelopmental changes in the brain will have taken place. Using similar rationale, the investigators chose to include participants up to the age of 59 because they do not want to include advancing age-related brain changes in our analyses. They will also be 6) fluent in English, as the testing and intervention are all conducted in English; and 7) will have been on stable doses of any psychotropic medications for the past 2 months, so as to avoid confounding of results by medication effects. It is expected that the sample included in this study will reflect the demographics of the greater Albuquerque and Twin Cities metropolitan communities
Who cannot take part
- Veterans will be excluded from participation in this study if there is 1) a prior history of other neurological disease or any history of seizures beyond immediate post-traumatic seizure, so as to reduce risk of exacerbation of epilepsy or other neurological symptoms; 2) history of psychosis, so as to reduce risk of psychiatric decompensation; 3) history of current or recent (within two years) substance/alcohol dependence, to reduce confounding effects on cognition; 4) any discontinuity in skull electrical conductivity (i.e., unhealed burr holes in scalp) or artificially constructed (metal or plastic) craniotomy cover, to reduce risk of unimpeded electrical current; 5) presence of any implanted metal or electrical device (e.g. pacemaker), to reduce risk of heating during MRI, or device malfunction during neuromodulation; 6) recent medical hospitalization (within three weeks), to reduce risk of medical decompensation during the study; 7) any condition that would prevent the participant from completing the protocol, such as significant agitation; 8) appointment of a legal representative, as assessed via direct inquiry of the participant or a designated trusted other, to avoid coercion of a vulnerable population; 9) any significant hardness of hearing or blindness that would make completing the cognitive training not possible; 10) any ongoing litigation related to TBI, to prevent interference with legal proceedings; 11) any other contraindication to exposure to strong magnetic fields or MRI, such as severe claustrophobia; 12) pregnant women will be excluded as the effects of MRI and brain stimulation on developing fetuses are unknown; 13) membership in an identified vulnerable population, including minors, and prisoners, and adults unable to consent due to cognitive impairment will be excluded, as they will be unlikely to be able to complete study procedures. Prisoners will be excluded from the study to avoid coercion; 14)received a Glasgow coma scale (GCS) less than 13 or greater than 15 upon ED admission, if available in patient's records
- The investigators do not intend to include adults who are unable to consent in this study
- The investigators do not intend to include individuals who are not yet adults (infants, children, teenagers) in this study
- The investigators do not intend to include pregnant women in this study
- The investigators do not intend to include prisoners in this study
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 59 years old?
Where in United States
- New Mexico Veterans Affairs Health Care SystemAlbuquerque, United StatesContact: JoAnn HarnarTaking people
- The Mind Research NetworkAlbuquerque, United StatesContact: Cesar J Ojeda, MBANo longer taking part
- The University of New MexicoAlbuquerque, United StatesContact: Cesar J Ojeda, MBANo longer taking part
- Minneapolis Veterans Affairs Medical CenterMinneapolis, United StatesContact: Sloan Davidson, MSTaking people
- The University of MinnesotaMinneapolis, United StatesContact: Cesar J Ojeda, MBANo longer taking part
About the trial
What the trial wants to find out
The CONNECT-TBI Trial aims to develop safe, effective treatments for complex mTBI that improve cognitive functioning. Based on the compelling preliminary data generated by our study team, the objective of this study is to conduct a randomized, double-blinded, sham-controlled Phase II clinical trial of APT-3 combined with rTMS, HD-tDCS, or sham to treat cognitive control deficits in Veterans with complex mTBI and PPCS. At the Baseline Visit, participants will undergo demographic, neuropsychological, behavioral, and quality of life testing. They will also undergo structural MRI to permit modeling of their brain, resting/task-related fMRI to identify the CCN, and pseudocontinuous arterial spin labeling (pCASL) and diffusion tensor imaging (DTI) to assess for other pathologies. They will then be randomized to 16 sessions of APT-3 with concurrent rTMS, HD-tDCS, or sham stimulation delivered to the unique functional left dorsolateral prefrontal cortex (DLPFC), a primary node of the CCN. Lastly, they will repeat all baseline tests, and report on 3- and 6-month recovery levels to establish longevity and stability of subjective benefit. Given that this individualization protocol has never been attempted for cognitive rehabilitation in military mTBI, we expect this trial will generate useful effect sizes for HD-tDCS and rTMS to be used for powering the next step, a Phase III multi-center trial.
The 4 groups in the trial
- Active rTMS with Attention Process TrainingExisting treatment, for comparison
Subjects in this arm will receive active rTMS and then complete the assigned Attention Process Training battery immediately following active rTMS.
Treatment: rTMS and Attention Process Training
- Sham rTMS with Attention Process TrainingSham treatment, for comparison
Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training immediately following sham rTMS.
Treatment: rTMS and Attention Process Training
- Active HD-tDCS with Attention Process TrainingExisting treatment, for comparison
Subjects in this arm will receive active HD-tDCS and complete the assigned Attention Process Training battery during active HD-tDCS.
Treatment: HD-tDCS and Attention Process Training
- Sham HD-tDCS with Attention Process TrainingSham treatment, for comparison
Subjects in this sham arm will not receive any active stimulation and will only complete Attention Process Training during sham HD-tDCS.
Treatment: HD-tDCS and Attention Process Training
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Criteria questions
- Built from NCT05236010, who can take part
- Publications
- Record updated
- 14 October 2026